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Abstract 
To study the activation of HIV by human spumare-
trovirus (HSRV) the long terminal repeats (LTRs) of 
HSRV, HIVl and HIV2 were examined with respect 
to their ability to function as transcriptional promo-
ters in virus infected and uninfected cells. Transient 
transfections using plasmids in which the L TRs of the 
three viruses were coupled to the bacterial chloram-
phenicol acetyltransferase (CA T) gene revealed (i) the 
Ievel of cat gene expression directed by the HSRV 
LTR was markedly increased in HSRV infected cells 
compared to uninfected cells, (ii) cat gene expression 
driven by the HIV1 LTR, but not by the HIV2 LTR 
could be enhanced upon HSRV infection, whereas 
(iii) neither in HIV1 nor in HIV2 infected cells an 
effect on HSRV LTR driven cat geneexpressionwas 
detected. 
Introduction 
It has been shown previously that the HIV LTR may 
be activated in trans by other viruses, and it has been 
suggested that this transactivation may be one factor 
leading to the progression from an asymptomatic sta-
tus ofinfection to clinical AIDS disease (1). The HIV 
LTR may be transactivated by DNA viruses (2), hepa-
titis B virus (3), and HTL VI tax-gene product ( 4 ), and 
in this case the genomic region of the HIV L TR 
responsible for transactivation has been mapped, 
(NFKB-MOTIF) (5). Thus, the study of transactiva-
tion of HIV by other viruses may (i) be of some value 
in the understanding of progression to clinical disease 
and may (ii) Iead to a better understanding of viral 
replication. 
HSRV belongs to the foamy subgroup ofretroviruses 
(6). Foamy viruses are ubiquitous in monkeys, bo-
vines, and felines, all of which are known to harbor 
lentiviruses closely related to HIV (7). There is only 
little knowledge on human foamy virus infections, but 
epidemiological data suggest natural virus presence in 
East African populations (8), a region with relatively 
high incidence of HIV infection (9). The genome of 
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HSRV has been molecular cloned and sequenced ( 1 0). 
Additional to gag, pol and env the HSRV genome 
bears sequences in the central and 3' region of the 
genome that are believed to have regulatory functions 
similar to the other human retroviruses (10). Espe-
cially a homology between the deduced amino acid 
sequence of one of the 3' open reading frames of 
HSRV and the HIV-2 tat protein suggests that HSRV 
encodes foraviral transactivator (11). 
Materials and Metbods 
Cells and viruses 
HSRV was grown on baby hamster kidney cells 
(BHK-21) as described (12). HIV1 and HIV2 were 
grown on H9 T cells as described (13). Cells were 
maintained in medium supplemented with 5 % fetal 
calf serum, glutamine and antibiotics. 
Plasmids 
Parent plasmid for the L TR cat constructs was 
pSV2cat (14). Deletion of a 500 bp Acci/Hindiii 
fragment containing the SV40 enhancer/promoter 
and insertion of Bglii or Hindiii-linkers led to plas-
mids pOcat-Bg and pOcat-H, respectively. A 1.5 kb 
Bglll fragment from pHSRV-B52 (9) containing the 3' 
L TR of HSRV was inserted in sense orientation into 
pOcat-Bg leading to pHSRVcat. pHIV1cat was de-
rived by inserting a 750 bp Hpai/Hindiii fragment 
from pHXB-2D (15) containing the 5' LTR of HIV1 
pCMVeat I hC MV enheneer/promoter 
+1J -170 
PHSRVeet I vr lua IR lus I 
-815 +3011 
pHIVleal jer I U3 IR I 
-412 +71 
pHIV2eat 
,., I U3 IR I 
-555 +151 
Fig. 1: LTR cat plasmids used for transfection experiments 
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into pOcat-H. pHIV2cat was a generaus gift ofDr. L. 
Montagnier. Control plasmid pCMVcat was con-
structed by inserting a 815 bp Hindillfragment from 
pRR23 containing the human cytomegalovirus im-
mediate early gene promoter/enhancer into pOcat-H. 
Plasmids are shown in Fig. I. 
Transfeetions and CA T assays 
Uninfected and HSRV infected BHK-21 cells were 
transfected with 10 J.Lg of plasmid DNA as described 
( 14 ). Cells were harvested 48 hrs after transfection and 
processed as described (14). Cat assays were per-
formed with equal amounts of protein, as determined 
using a commercial protein assay (Biorad), 0.1 J.LCi 
14C-chloramphenicol (Amersham) and 0.8 mM ace-
tyl-CoA. Unacetylated chloramphenicol was separ-
ated from acetylated chloramphenicol by thin layer 
chromatography, and quantification was done by cut-
ting out the spots from the chromatography plate and 
liquid scintillation counting. 
RNA extraction and Northern bJotting 
RN A was extracted from pHSRV cat transfected cells 
by the guanidinum isothiocyanate method (16). Poly 
A+ RNA was selected on oligo (dT) cellulose, RNA 
was run on formaldehyde containing agarase gels, 
and blotted onto nylon membranes (DuPont). Filters 
were hybridized with a cat specific probe as described 
(17) and exposed to X-ray film (DuPont). 
ResuJts 
Demonstration of transactivation in HSRV infected 
celJs 
Uninfected and HSRV infected BHK-21 cells were 
transfected with pHSRVcat. RNA was extracted from 
transfected cultures and poly A + RNA was hybridized 
with a cat specific probe. As shown in Fig. 2 cat 
mRNA could only be observed in HSRV infected cells 
(lane b ), but not in uninfected cells (lane a). The filter 
was rehybridized with a ß-actin probe to demonstrate 
equal amounts of RNA in both lanes. The percentage 
of acetylated chloramphenicol from total input chlor-
amphenicol was determined from CA T assays per-
formed with lysates from cultures tansfected in paral-
lel. The conversion rate was 64.6% in HSRV infected 








ß -act in 
% conversion 
Fig. 2: Northern blot ofcat mRNA inBHK-21 cel/s(a), andHSRV 
infected BHK-21 cel/s (b) transfeered with pHSRVcat 
Transactivation of HIV by HSRV 
Plasmids pHSRVcat, pHIV1cat and pHIV2cat were 
transfected in HSRV infected and uninfected cells. 
Transfeetion with pSV2cat and pCMVcat seved as 
control. Table 1 shows a summary ofthree independ-
ent transfections and CAT assays. While transfection 
of control plasmids into uninfected cells results in 
expected Ievels of CAT activity, the LTRs are silent 
(HSRV) or almost silent (HIV1 and HIV2) in these 
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Table 1: Compilation of CAT assays 
BHK-21 BHK-21/HSRV H9/HIV1 H9/HIV2 
% acetylation rel.% % acetylation rel.% % acetylation % acetylation 
pSV2cat 39.7 1.00 79.3 
pCMVcat 40.9 1.03 95.6 
pHSRVcat 0.7 0.02 57.7 
pHIVlcat 2.3 0.06 33.0 
pHIV2cat 2.2 0.06 
n.d. = not done 
cells. In HSRV infected cells expression from the con-
trol plasmids is enhanced by a factor of about 2, while 
enhancement with pHSRVcat was found tobe about 
80 fold. Respective values for pHIVlcat were 14 fold 
enhancement, and for pHIV2cat were 3 fold en-
hancement. To normalize the CA T activity obtained 
from transfection with different plasmid all values 
were expressed in relation to the CA T activity ob-
tained with pSV2cat. Following this calculation tran-
sactivation in HSRV infected cells was found to be 
36.5 fold (with pHSRVcat), 7 fold (with pHIVlcat) 
and 1.5 fold (with pHIV2cat). 
To test whether either HIV1 or HIV2 infection may 
lead to transactivation of the HSRV L TR, plasmids 
were transfected into HIV1 or HIV2 infected H9 cells. 
As shown in Table 1 transfection of HIV1cat and 
HIV2cat into HIV1 or HIV2 infected cells 1eads to the 
expected expression of CAT activity, while neither in 
HIV1 nor in HIV2 infected cells an effect on HSRV 
L TR driven cat gene expression could be detected. 
Conclusion 
Herewe have presented evidence for a transactivator 
in HSRV infected cells able to enhance activity ofthe 
HSRV and HIV1 LTR, but not of the HIV2 LTR. 
While Northern blotting of cat mRNA from trans-
fected cultures suggests that transactivation of the 
HSRV L TR mainly occurs at the transcriptionallevel, 
the mechanism of transactivation of the HIV1 LTR is 
still unclear. We found that transfection of control 
plasmids resulted in a higher level of cat activity in 
infectd cells than in uninfected cells. This effect may 
either be due to an easier transfectability of HSRV 
infected cells than in uninfected cells or may be the 
result of transactivation by an indirect mechanism as 
6.8 
1.00 n.d. n.d. 
1.20 n.d n.d. 
0.73 0.4 0.3 
0.42 77.5 n.d. 
0.09 n.d. 87.5 
described for pSV2cat and HTLV I tax (18). Further 
experiments are necessary to answer this question. T o 
study the mechanism by which HSRV transactivates 
its own and the HIV1 LTR we have constructed an 
infection mo1ecular clone for HSRV (A. Rethwilm et 
al., manuscript in preparation) and are currently con-
structing deletion mutants of this clone to map the 
HSRV specific transactivator. 
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